Abstract
Glioblastoma multiforme (GBM), the most common and aggressive form of primary brain tumor, presents a dismal prognosis. Current standard therapies are only able to improve patient survival by a few months. The search for alternative approaches in glioblastoma treatment, together with the recent discovery of a new class of small RNA molecules that are capable of regulating gene expression, prompted a race for a deeper and thorough understanding of how these molecules work. Today, it is known that microRNAs are involved in many cellular processes that are altered in GBM tumors, such as angiogenesis, invasion, cell proliferation and apoptosis. Research in this area is now gathering efforts to translate these findings into clinically relevant therapies that could improve the diagnosis and outcome of GBM patients. In this review, we discuss the use of microRNAs as potential diagnostic, prognostic and therapeutic tools against glioblastoma. We will also assess the current challenges and future perspectives of microRNA-based therapies, with a special focus on why this promising therapeutic approach is not yet in the clinic and how to overcome this limitation.
Keywords: Challenges, diagnostic, glioblastoma multiforme, microRNA, oncogenes, prognostic, therapeutic approaches, tumor suppressors
Current Molecular Medicine
Title:MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Volume: 13 Issue: 4
Author(s): B. Auffinger, B. Thaci, A. Ahmed, I. Ulasov and M.S. Lesniak
Affiliation:
Keywords: Challenges, diagnostic, glioblastoma multiforme, microRNA, oncogenes, prognostic, therapeutic approaches, tumor suppressors
Abstract: Glioblastoma multiforme (GBM), the most common and aggressive form of primary brain tumor, presents a dismal prognosis. Current standard therapies are only able to improve patient survival by a few months. The search for alternative approaches in glioblastoma treatment, together with the recent discovery of a new class of small RNA molecules that are capable of regulating gene expression, prompted a race for a deeper and thorough understanding of how these molecules work. Today, it is known that microRNAs are involved in many cellular processes that are altered in GBM tumors, such as angiogenesis, invasion, cell proliferation and apoptosis. Research in this area is now gathering efforts to translate these findings into clinically relevant therapies that could improve the diagnosis and outcome of GBM patients. In this review, we discuss the use of microRNAs as potential diagnostic, prognostic and therapeutic tools against glioblastoma. We will also assess the current challenges and future perspectives of microRNA-based therapies, with a special focus on why this promising therapeutic approach is not yet in the clinic and how to overcome this limitation.
Export Options
About this article
Cite this article as:
Auffinger B., Thaci B., Ahmed A., Ulasov I. and Lesniak M.S., MicroRNA Targeting as a Therapeutic Strategy Against Glioma, Current Molecular Medicine 2013; 13 (4) . https://dx.doi.org/10.2174/1566524011313040006
DOI https://dx.doi.org/10.2174/1566524011313040006 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
FAT10: Function and Relationship with Cancer
Current Molecular Pharmacology Cannabinoids: Between Neuroprotection and Neurotoxicity
Current Drug Targets - CNS & Neurological Disorders Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19
Current Pharmaceutical Design C-Methionine PET/CT in Central Nervous System Tumours: A Review
Current Radiopharmaceuticals Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Antibody Targeting of TGF-β in Cancer Patients
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Anti-Angiogenesis and RGD-Containing Snake Venom Disintegrins
Current Pharmaceutical Design DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Imidazoquinolines: Recent Developments in Anticancer Activity
Mini-Reviews in Medicinal Chemistry Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
Current Pharmaceutical Design Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Poly(Ethylene Glycol) Amphiphilic Copolymer for Anticancer Drugs Delivery
Anti-Cancer Agents in Medicinal Chemistry Antidepressant Desipramine Leads to C6 Glioma Cell Autophagy: Implication for the Adjuvant Therapy of Cancer
Anti-Cancer Agents in Medicinal Chemistry Biomedical Technologies for In Vitro Screening and Controlled Delivery of Neuroactive Compounds
Central Nervous System Agents in Medicinal Chemistry Dendrimers: Nanosized Multifunctional Platform for Drug Delivery
Drug Delivery Letters Stable Expression of the Sodium/Iodide Symporter (NIS) for anti-Cancer Gene Therapy of Glioma Cells Using a Third Generation Self-Inactivating Lentiviral Vector System in Combination with 211At
Current Radiopharmaceuticals Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine
Current Pharmaceutical Design